Cover Image
市場調查報告書

全球動物用診斷藥市場:各產品、動物、地區 - 趨勢及預測

Global Veterinary Diagnostics Market - Growth, Trends and Forecast (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 319380
出版日期 內容資訊 英文 95 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球動物用診斷藥市場:各產品、動物、地區 - 趨勢及預測 Global Veterinary Diagnostics Market - Growth, Trends and Forecast (2018 - 2023)
出版日期: 2018年02月08日 內容資訊: 英文 95 Pages
簡介

全球動物用診斷藥市場預計2014年達15億9,000萬美元。動物用蛋白質的需求持續增加、食品安全相關法規嚴格化,促進市場擴大。預計該市場今後以年複合成長率4.6%穩定擴大,至2019年達20億2,000萬美元規模。

本報告提供全球動物用診斷藥市場趨勢與未來預測、打入市場的主要企業的競爭環境、市場佔有率、近幾年趨勢與簡介彙整。

第1章 簡介

第2章 市場分析

  • 動物醫療產品市場
  • 動物醫療和人的醫療

第3章 市場趨勢

  • 推動市場的要素
    • 寵物擁有率的上升
    • 營養的改善
    • 消費者對食品安全的認知提高
    • 家畜生產的增加
    • 人畜共通感染疾病,經由食物傳染疾病
  • 阻礙市場的要素
    • 耕種地和水的不足
    • 耕地相關競爭激烈
    • 成本效益高的生產
  • 波特五力分析

第4章 全球動物用診斷藥市場區隔

  • 各產品
    • 簡介
    • 免疫診斷檢驗
  • 各類型
    • 寵物
    • 家畜
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區

第5章 競爭環境

  • 市場上主要加入企業
  • 合併、收購
  • 新產品上市
  • 協定、聯合、聯盟
  • 對新加入廠商的建議
  • 對老字號企業的建議

第6章 企業簡介

  • Zoetis animal healthcare
  • Merck
  • Merial (Animal Health Division Of Sanofi)
  • Elanco
  • Bayer healthcare
  • Novartis Animal Health, Inc.
  • Virbac
  • Boehringer Ingelheim

第7章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 9922

Description

The global veterinary diagnostics market accounted for around 22% of the entire veterinary healthcare market. Veterinary diagnostics has potential applications in the diagnosis and management of several animal diseases, such as foot-and-mouth disease, classical swine fever, avian flu, and bovine spongiform encephalopathy, etc. This factor is fuelling the market in spite of hindrances like shortage of veterinarians in emerging markets. The market is expected to register a CAGR of 7.91% by 2023, with 55% increase in the overall market, during 2018-2023 (the forecast period).

PHAROS DIAGNOSTICS EXPANDS INTO VETERINARY DIAGNOSTICS MARKET

From 2017, Pharos diagnostics is expanding into Veterinary diagnostics. It will be among the first diagnostic laboratories to offer mass spectrometry into the Veterinary diagnostics market, which is widely regarded as the most accurate and sensitive scientific method for measuring drugs, hormones, and other analytics in, both, humans and animals. Technology improvements of the last decade, like mass spectrometry, have not completely entered the veterinary diagnostic market, especially, when compared to the human medicine. Traditionally, veterinarians had to choose between expensive, slow, and sometimes inaccurate testing options while performing testing. The expansion of Pharos in Veterinary diagnostics is anticipated to change the scenario. The key benefits to veterinary market will be increased accuracy in testing, with faster turnaround time, coupled with cost efficiency. The mass spectrometer platform, employed by Pharos diagnostics, allows multiple tests to be performed using the same sample. Since smaller sample can often be obtained using less intrusive methods, there would be less hassle for the veterinarian and a better experience for the consumer.

INCREASING TRANSGENIC TECHNOLOGIES IN VETERINARY DIAGNOSIS

Currently, breakthroughs in molecular biology are occurring at an unprecedented rate. One of them is the ability to engineer transgenic animals, i.e. animals that carry genes from other species. The technology has already produced transgenic animals, such as mice, rats, rabbits, pigs, sheep, and cows. Transgenic technologies are used for producing specific economic traits, like improving productivity in farm animals as well as for production of proteins for human medical use. A few instances include:

Transgenic cattle were created by scientists to produce milk containing particular human proteins, which may help in the treatment of human emphysema.

College of Veterinary Medicine at Northwest A&F University in Shaanxi, China, has successfully utilized an innovative form of the genome-editing technique CRISPR to produce Tuberculosis-Resistant Cows.

Transgenic fish: Technicians in Indiana created fertilized Atlantic salmon eggs that include growth-enhancing DNA from two other fish species after getting approval from USFDA.

Apart from this, transgenic animals are also produced as disease models. For instance, Harvard scientists made a major scientific breakthrough when they received a US patent (the company DuPont holds exclusive rights to its use) for a genetically engineered mouse, called OncoMouse® or the Harvard mouse, carrying a gene that promotes the development of various human cancers, in 1984. This was the first transgenic mammal being patented. These developments have certainly made the use of Veterinary diagnostics a primary need for the nations

TECHNOLOGICAL ADVANCEMENTS LEADING TO NEW AND EFFICIENT EQUIPMENT AND PROCEDURES IN VETERINARY DIAGNOSTICS

While Veterinary diagnostics are primarily comprised of time-tested, traditional diagnostic techniques, a profound change has occurred in recent years with the introduction of new biotechnological assays. These new biotechnologies include the production of more specific antigens by the use of recombination, expression vectors, and synthetic peptides. Coupled with the use of monoclonal antibodies, the sensitivity and specificity of a number of traditional types of diagnostic assays have been significantly improved. Various forms of PCR (polymerase chain reaction) assay have become routine diagnostic tools in Veterinary laboratories, not only to make specific typing determinations but to rapidly screen a large number of samples during disease outbreaks. More efficient and accurate technologies are likely to be developed and widely adopted in the future, as they demonstrate the ability to improve diagnostic capabilities while reducing the time and, perhaps, the cost associated with more conventional technologies. A few of these efficiently used technologies include genetic engineering done in farm animals and nuclear transfer technology for cloning animals, gene therapy for diseases of pet animals, and RNA interference technology. Molecular diagnosis and polymerase chain reaction with its modifications are also assuming an important place in veterinary practice. While the fluorescent in situ hybridization and enzyme-linked immunosorbent assays have become widely used, the newer biochip-based technologies and biosensors are also finding their way in Veterinary diagnostics.

UNTAPPED EMERGING MARKETS TO BE THE PRIMARY FOCUS OF MAJOR MARKET PLAYERS

The North American and European Veterinary diagnostics markets have large shares, owing to the increasing companion animal population, coupled with the positive trend towards animal healthcare spending. Developing countries in Asia-pacific and South America are expected to form a new revenue generator in the market, with India, China, and Brazil occupying major market share over the next decade.

Major Players : ABAXIS, HENRY SCHEIN, HESKA CORPORATION, IDVET, PFIZER, THERMO FISHER SCEINTIFIC, VIRBAC, ZOETIS amongst others.

Reasons to Purchase this Report

Analyzing various perspectives of the market with the help of Porter's five forces analysis.

Study on the regions that are expected to witness fastest growth during the forecast period.

Identify the latest developments, market shares and strategies employed by the major market players.

3 months analyst support along with the Market Estimate sheet (in excel).

Customization of the Report

This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs

Table of Contents

1. Introduction

  • 1.1. Research Methodology
  • 1.2. General Study Assumptions

2. Research Methodology

  • 2.1 Introduction
  • 2.2 Analysis Methodology
  • 2.3 Study Phases
    • 2.3.1 Secondary Research
    • 2.3.2 Discussion Guide
    • 2.3.3 Market Engineering & Econometric Modeling
    • 2.3.4 Expert Validation
  • 2.4 Study Timeline

3. KEY FINDINGS OF THE STUDY

4. MARKET OVERVIEW

  • 4.1 Introduction
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
      • 4.2.1.1 Increased pet ownership
      • 4.2.1.2 Intensifying consumer focus on food safety
      • 4.2.1.3 Increasing zoonotic and Foodborne diseases
      • 4.2.1.4 Improved Nutrition
    • 4.2.2 Restraint
      • 4.2.2.1 Scarcity of arable land and water
      • 4.2.2.2 Increased competition for cultivated land
    • 4.2.4 Porter's Five Forces Analysis
      • 4.2.4.1 Bargaining Power of Suppliers
      • 4.2.4.2 Bargaining Power of Buyers
      • 4.2.4.3 Threat of New Entrants
      • 4.2.4.4 Threat of Substitute Products and Services
      • 4.2.4.5 Degree of Competition

5. MARKET SEGMENTATION

  • 5.1 By Type of Diagnostic Test
    • 5.1.1 Immunodiagnostic Tests
      • 5.1.1.1 Enzyme linked Immuno-sorbent assay (ELISA)
      • 5.1.1.2 Rapid Immuno Migration (RIM)
      • 5.1.1.3 Agar Gel Immuno-diffusion (AGID)
      • 5.1.1.4 Others
    • 5.1.2 Molecular Diagnostics
      • 5.1.2.1 Polymerase Chain Reaction (PCR)
      • 5.1.2.2 Microarrays
      • 5.1.2.3 Sequencing (DNA & NGS)
      • 5.1.2.4 In-Situ Hybridization (ISH)
      • 5.1.2.5 Others
    • 5.1.3 Diagnostic Imaging
      • 5.1.3.1 Ultrasound Imaging
      • 5.1.3.2 MRI Scanning
      • 5.1.3.3 Others
    • 5.1.4 Hematology Analyzers
    • 5.1.5 Clinical Chemistry
    • 5.1.6 Others
  • 5.2 By Animal Type
    • 5.2.1 Farm Animals
      • 5.2.1.1 Cattle
      • 5.2.1.2 Swine
      • 5.2.1.3 Poultry
      • 5.2.1.4 Fish
      • 5.2.1.5 Sheep
    • 5.2.2 Companion Animals
      • 5.2.2.1 Dogs
      • 5.2.2.2 Cats
      • 5.2.2.3 Horse
  • 5.3 By Product
    • 5.3.1 Consumables
    • 5.3.2 Instruments
  • 5.4 By Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 UK
      • 5.4.2.2 France
      • 5.4.2.3 Germany
      • 5.4.2.4 Spain & Portugal
      • 5.4.2.5 Italy
      • 5.4.2.6 Scandinavia
      • 5.4.2.7 BENELUX
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 South Korea
      • 5.4.3.5 Australia & New Zealand
    • 5.4.4 Latin America
      • 5.4.4.1 Brazil
      • 5.4.4.2 Argentina
    • 5.4.5 Middle East & Africa
      • 5.4.5.1 GCC
      • 5.4.5.2 Morocco
      • 5.4.5.3 Algeria
      • 5.4.5.4 South Africa

6. COMPETITIVE LANDSCAPE

  • 6.1 Mergers & Acquisition
  • 6.2 Agreements, Collaborations and Partnerships
  • 6.3 New Product Launches

7. COMPANY PROFILES

  • 7.1 Pfizer
  • 7.2 Thermo Fisher Scientific
  • 7.3 Henry Schein
  • 7.4 Virbac
  • 7.5 Zoetis
  • 7.6 IDVet
  • 7.7 Abaxis
  • 7.8 Heska Corporation
  • 7.9 Idexx
  • 7.10 Biochek
  • 7.11 VCA Antech
Back to Top